 |
12 Diseases |  |
14 Trials |
|
14 Trials |  |
524 News |  |
| «123456789 |
- || Isentress (raltegravir) / Merck (MSD)
New P3 trial, Combination therapy: RALAM: Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (clinicaltrials.gov) - Nov 5, 2014
P3, N=75, Not yet recruiting, Sponsor: Juan A. Arnaiz
- ||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Na (clinicaltrials.gov) - Oct 15, 2014
P3, N=400, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting
- |||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial primary completion date: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Na (clinicaltrials.gov) - Oct 10, 2014
P3, N=400, Recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2015 --> Oct 2015
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open, Trial primary completion date: Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (clinicaltrials.gov) - Sep 15, 2014
P2, N=53, Recruiting, Sponsor: Nantes University Hospital
Trial primary completion date: Jul 2015 --> Oct 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2015
- |||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Jun 17, 2014
P3, N=538, Recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial initiation date: ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (clinicaltrials.gov) - Jun 4, 2014
P3, N=25, Not yet recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Jun 2014
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - May 4, 2014
P3, N=538, Not yet recruiting, Sponsor: ViiV Healthcare
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (clinicaltrials.gov) - Apr 3, 2014
P3, N=538, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial: ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection (clinicaltrials.gov) - Feb 27, 2014
P3, N=25, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P2 trial: Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (clinicaltrials.gov) - Feb 18, 2014
P2, N=53, Not yet recruiting, Sponsor: Nantes University Hospital
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-na (EUDRACT) - Nov 11, 2013
P3, N=15, Ongoing, Sponsor: Unidad de VIH - Servicio de Enfermedades Infecciosas. Hospital de Bellvitge
- |||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment open: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Na (clinicaltrials.gov) - Sep 11, 2013
P3, N=474, Recruiting, Sponsor: ViiV Healthcare
Initiation date: Mar 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- |||||||||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P3 trial: A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Na (clinicaltrials.gov) - Jul 25, 2013
P3, N=474, Recruiting, Sponsor: ViiV Healthcare
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment change: Evaluation of the Bioequivalence of a Combined Formulated Tablet (clinicaltrials.gov) - Oct 10, 2012
P1, N=66, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting N=52 --> 66
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial completion: Evaluation of the Bioequivalence of a Combined Formulated Tablet (clinicaltrials.gov) - Sep 19, 2012
P1, N=66, Completed, Sponsor: ViiV Healthcare
N=52 --> 66 Active, not recruiting --> Completed
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
New P1 trial: Evaluation of the Bioequivalence of a Combined Formulated Tablet (clinicaltrials.gov) - Jun 17, 2012
P1, N=66, Completed, Sponsor: ViiV Healthcare